Home » Newsletters » BioWorld Science

BioWorld Science

June 24, 1998

View Archived Issues

Select Therapeutics signs agreement for cancer vaccine platform technology

Anseculin continues in phase II after successful testing in older volunteers

Abbott patents improved ketolide antibacterial agents

Substituted carbapenems for Gram-positive infections designed at Merck & Co.

Idun discloses new inhibitors of ICE and related proteases

Aspirin improves MS-related fatigue

S-16020-2: a topoisomerase II inhibitor selective for renal cancers heads for phase II testing

Progenics receives payment for cancer vaccine milestone

Miproxifene phosphate, a promising treatment for breast cancer

Management strategy including hydroxyurea successful in unresectable meningioma

Phase II evaluation of carzelesin in NHL

Sheffield and Zambon collaborate on MSI delivery system for respiratory drugs

Introgen Therapeutics acquires exclusive option to license PTEN gene

Duract withdrawn from the U.S. market due to reports of hepatotoxicity

Potent angiogenesis inhibitor AG-3340 profiled at NCI-EORTC symposium

Nabi licenses technology for development of antiviral drug

Canadian launch for improved antihypertensive medication

Draximage announces strategic alliance with Molecular Targeting Technology

Zeldox deemed nonapprovable by the FDA

Pharmacia & Upjohn licenses rights to novel JT diabetes drug

City of Hope identifies novel target for diabetes intervention as part of Cell City joint venture

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...